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The AIDS epidemic caused by the human immunodeficiency virus type 1 (HIV-1) 
continues to escalate but a protective vaccine remains elusive. With 33 million people 
infected world wide, 2.7 million people infected in 2007 (UNAIDS), and with a high 
mortality (2 million deaths in 2007), HIV is one of the most lethal pathogens.  Thus, 
a vaccine and or better treatment are urgently needed. 
To develop effective strategies, deep knowledge and detailed insights into HIV 
biology, its origin and interaction with the host immune system are crucial. In recent 
years, approaches to trigger CD8+ T-cell responses for eradication of HIV looked 
promising, but do not prevent primary infection. Thus, neutralizing antibodies (nAbs) 
are the preferential choice to effectively neutralize viral particles before establishing a 
systemic infection. To study nAbs, the simian-human immunodeficiency virus 
(SHIV)-macaque model has been shown to most likely mimic the natural way of 
infection in humans. The development of various chimeric SHIVs carrying HIV 
envelope sequences represents a great tool to screen and test vaccine efficacy. 
However, these SHIVs have to fulfill some important criteria to reflect the situation 
of HIV infection seen in humans.  
The majority of primary infections in humans are with HIV-1 clade C, the 
predominant strain worldwide. Thus, new SHIV models should reflect this situation 
and carry envelopes from clade C. Ninety percent of all transmissions occur mucosally 
and among these, almost all involve R5 viruses. Current SHIV models lack at least 
one of these properties, if not all, and need to be replaced with mucosally 
transmissible R5 SHIVs. 
In this work, we describe the construction of a SHIV which a) carries a clade C 
envelope, b) uses CCR5 as coreceptor, c) is mucosally transmissible and d) is 
neutralization sensitive to allow assessment of nAb efficiency upon vaccination. 
Through molecular cloning techniques, we could exchange the major envelope region 
of an already used SHIV with the early-form envelope of an HIV-1 isolated from a 
Zambian child. 293T cells were then transfected with the full-length genome of the 
new SHIV; virus was produced in these cells and tested for functionality in TZM-bl 
cells (modified HELA cells containing an infection-responsive reporter gene). A viral 
stock was grown and after neutralization susceptibility evaluation, we could show 
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1.1 The Human Immunodeficiency Virus (HIV) 
 
In the 20th century, human immunodeficiency virus 1 and 2 (HIV-1, HIV-2) were 
introduced to the human population. HIV is a member of the Retroviridae and 
belongs to the family of lentiviruses and as such contains two positive-sense RNA 
strands that are reverse transcribed to double-stranded DNA in the host by the error-
prone enzyme reverse transcriptase (see 1.1.2.3). Based on genetic variation of the 
surface envelope glycoprotein gp160, HIV-1 falls into three groups: M (Major/Main), 
N (Non-M, Non-O/New) and O (Outlier) – of which group M is the most common 
and is subdivided into clade A-H, J, K and many circulating recombinant forms 
(CRFs) and unique recombinants– of which clade B is mainly spread in Europe and 
the USA and clade C is primarily found in India, China and sub-Saharan Africa and 
causes the most infections. Following a study of UNAIDS, the global distribution of 
HIV-1 subtypes, based on sequence differences in the envelope, is dominated by clade 
C (56%), followed by clade A (25%), clade B (12%) and clade D, E and minor 
subtypes (each ~4%). 
 
1.1.1 Discovery and Origin 
 
In the 1980s, three independent groups (Francoise Barré-Sinoussi, Claude Chermann 
and Luc Montagier [6], Robert Gallo and colleges [7] and the group of Jay A. Levy 
[8]) discovered a new retrovirus that was associated with an acquired 
immunodeficiency and was named human immunodeficiency virus (HIV) by an 
international committee in the year 1984 [9, 10].  
Human immunodeficiency viruses HIV-1 and HIV-2, the causative agents of the 
acquired immunodeficiency syndrome (AIDS), were introduced to the human 
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population in Africa during the 20th century [11, 12]. Many species of non-human 
primates are naturally infected with closely related lentiviruses, but, curiously, AIDS is 
mostly not observed in the natural hosts. Phylogenetic analysis revealed that HIV-1 
evolved from a simian immunodeficiency virus strain SIVcpz, which can be found in a 
subspecies of chimpanzee (Pan troglodytes troglodytes) and infected humans probably 
around the 1930ths. The less pathogenic HIV-2 originated from SIVsm of sooty 
mangabeys (Cercocebus atys), having approximately 40-60% homology to HIV-1 [3]. 
These viruses were transferred to the human population via cross-species 
transmission, but only one SIVcpz ancestor gave rise to the global AIDS pandemic: 
HIV-1 group M with clades A to K. Group M, as well as group N arose from a 
geographically distinct chimpanzee population in Cameroon [13]. 
 
1.1.2 Assembly and Genome Structure 
 
The viral genome, the production of viral proteins and the viral assembly are 
summarized in the following chapters. For a more detailed review of all HIV features 
and its life cycle, readers a referred to a review by B. Matija Peterlin and Didier 
Trono, [14]. 
 
1.1.2.1 Structure of the Viral Particle 
 
On transmission electron microscopy (TEM) pictures, HIV appears as a 100 nm 
round spiked particle (Figure 1). The spikes are formed by trimers of the envelope 
glycoprotein units gp120 (surface glycoprotein; outer part) and gp41 (transmembrane 
part), which adhere by hydrophobic and hydrophilic interactions, advancing 
conformational changes leading to membrane fusion with the target cell. Gp120 is 
heavily glycosylated; different sugar residues take around 58% of its total mass [15, 
16]. 
The outer shell of the virus is comprised by a double phospholipid bilayer that 
originates from the host cell after budding off of the virus and thereby includes several 
host membrane proteins, e.g., MHC molecules. Linked to the membrane are the p17 
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Fig. 1 | Schematic draw of an HIV particle
Modified from The challenges of eliciting neutralizing antibodies 
to HIV-1 and to influenza virus by Karlsson Hedestam et al. 
Nature Reviews Feb. 2008 [4]
matrix proteins (MA); both the lipid bilayer and the MA are termed the outer core of 
the virus. 
The cone-shaped inner core (capsid) consists of p24 capsid proteins (CA) and 
contains the two identical positive sense RNA molecules, stabilized by p7 
nucleocapsid proteins (NC). The proteins reverse transcriptase (RT, p51), RNase H 
(p66) and integrase (IN, p32) bind to the NC proteins as well. Two copies of the 
tRNALys3, needed for initiation of reverse transcription, and the accessory proteins Nef 
(negative effector) and Vif (viral infectivity factor) can also be found in the capsid. 
The viral proteins Tat (transcriptional transactivator), Rev (regulator of virion gene 
expression) and Vpu (viral protein u) cannot be found in the viral particle, but in the 
infected cell. The inactive viral protease (p10) can be found in between the matrix and 













1.1.2.2 Genome Organization 
 
Integrated into the host chromosome, the 10 kb genome of HIV contains open 
reading frames for 16 proteins (Figure 2). The classical structural and enzymatic 
proteins derived from the genes gag (group-specific antigen), pol (polymerase) and env 
(envelope) are required by all retroviruses. In addition, HIV encodes two regulatory 





Fig. 2 | HIV genome, transcripts and proteins
a | The 10 kb genome of HIV contains ORFs for 16 proteins, 
8 transcripts are shown in this figure. b | The synthesized 
precursor proteins get processed by viral (yellow box) and 
cellular (red box) proteases. 
expression), and the accessory proteins Nef (negative effector), Vif (viral infectivity 
factor), Vpr (viral protein r) and Vpu (viral protein u). The accessory proteins are not 
required for viral replication in vitro but enhance infectivity in vivo. 
All viral proteins are synthesized by more than 30 messenger RNAs, which are all 
derived from the primary 
transcript but expressed 
and translated differently 
during the course of 
infection. The early 
transcripts for Tat, Rev 
and Nef are fully spliced, 
those that encode the late 
viral proteins, mainly 
structural and enzymatic 
components and factors 
that fine-tune infectivity, 
are singly single spliced or 
unspliced. The transition 
between the early and the 
late phase of the viral gene 
expression is regulated by 
Rev by binding to the Rev 
response element (RRE) 
and transport of singly 
spliced or unspliced viral 
mRNA from the nucleus 
to the cytoplasm. 
Expression of viral genes is 
regulated by the long 
terminal repeat (LTR), 
which flanks the genome on 
the 5’ and the 3’ side. It 
contains enhancer and promoter sequences with binding sites for several transcription 
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factors and a polyadenylation signal. The enhancer sequence binds the nuclear factor-
KB (NF-KB), the nuclear factor of activated T cells (NFAT), as well as members of 
the ETS family of transcription factors [transcription factors containing the unique 
erythroblast transformation specific (ETS) DNA binding domain] [17] which ensures 
a high replication efficacy in activated T cells and differentiated macrophages. Further 
downstream, three SP1-binding sites, the TATA box, the initiator (Inr) and the 
transcription start are found. The most unusual feature of the LTR is the presence of 
a strong regulatory element located 3`to Inr. This RNA structure, which is known as 
the transactivation response (TAR) element, is found at the 5’ end of all viral 
transcripts and binds Tat. In the absence of Tat, HIV transcription begins, but 
elongation is inefficient. Tat and its cellular co-factor, positive transcription 
elongation factor b (P-TEFb), cooperate to bind TAR with high affinity. The ability 
of Tat to recruit P-TEFb through an RNA sequence is unique among transcriptional 
activators, and it renders HIV replication particularly sensitive to inhibition of CDK9 
(a component of P-TEFb). Although NF-KB can partially substitute for Tat, as it can 
itself recruit P-TEFb, Tat leads to higher levels of gene expression and is essential for 
HIV replication in the host [14].  
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1.1.2.3 The Replicative Cycle 
 
 
Figure 3 | The replicative cycle of HIV. The viral envelope protein binds CD4 first, leading to a 
conformational change and the binding of a co-receptor, either CCR5 or CXCR4, defining the 
tropism of the viral strain (R5 or X4). After fusion of the membranes, viral RNA gets reverse 
transcribed and transported through the microtubular network of the cell and the nuclear pores into the 
nucleus after the assembly of the so-called pre-integration complex. Viral DNA integrates and forms 
the pro-virus. After time-controlled transcription, splicing and translation, viral proteins get 
transported to lipid rafts in the cell membrane, where an immature virion assembles. After processing 
of Gag and Gag-Pol, the mature HIV virus buds off the cell membrane. [14] 
 
HIV enters the body through exchange of body fluids and infects mainly T helper 
(TH) cells, macrophages and to some extent, microglia cells and dendritic cells (DCs). 
Besides the use of CD4 as main receptor, the use of co-receptors after binding of 
CD4 and conformational change of envelope protein gp120, determines this target 
cell tropism. HIV R5 strains, detected in the early phase of infection, use CC-
chemokine receptor 5 (CCR5) as their co-receptor and can, therefore, enter 
macrophages, DCs and T cells (mainly memory T cells), whereas X4 strains of HIV, 
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predominating with time, use CXCR4 as a co-receptor and can infect T cells (naïve T 
cells) only [18]. 
DCs are likely to play an important role in transporting the virus to lymphoid organs, 
as these cells can either be productively infected or capture the virus through the 
lectin-like receptor DC-SIGN (DC-specific ICAM3-grabbing non-integrin) and 
store the virus in an infectious form before presenting it to T cells [19, 20]. 
 
After binding of both, receptor (CD4) and co-receptor (CCR5/CXCR4), and further 
conformational changes in the envelope protein, HIV fuses with the host membrane 
[21], uncoats and reverse transcribes its two RNA molecules (with recombination 
events) into a double stranded DNA that is transported with the so-called pre-
integration complex, a complex of integrase, matrix, viral protein r and viral DNA, 
into the nucleus. Because of the large number of nuclear-localization signals on the 
proteins of the pre-integration complex [22-24], a disintegration of the nuclear 
membrane, and therefore cell division, is not required for the nuclear import of the 
viral DNA. 
Once in the nucleus, the viral DNA gets integrated via the help of integrase and 
several chromatin remodeling complexes [25] with preference for active genes. 
However, in resting lymphocytes, there are several barriers that preclude the 
completion of these early steps due to low energy levels, leading to accumulation of 
double-stranded viral genomes. Nevertheless, once the lymphocytes get activated, 
even partially, they become fully permissive for HIV to complete the replication cycle 
[26-28]. 
After integration, the now called pro-virus behaves like any other gene, with its 
promoter in the 5’ LTR region and a poly-adenylation site in the 3’ LTR, as described 
in 1.1.2.2. The viral genes get transcribed, spliced and translated in a time-dependent 
manner, controlled by Rev. After translation, viral structural and enzymatic proteins 
travel to the plasma membrane, where immature virions assemble in cholesterol-rich 
lipid rafts. Nef is important for this assembly and the viral protease p10 processes Gag 






1.2 The Natural History of Infection 
 
1.2.1 Infection and Progression to AIDS 
 
After infection with HIV, either by sexual intercourse, blood-blood contact or breast 
feeding, the immune system reacts like it does for any other viral infection. First, 
infected cells get lysed by natural killer (NK) cells and cytotoxic T lymphocytes 
(CTL). Second, following this cell-mediated immune response, B cells produce 
immunoglobulin M (IgM) after a time course of two to three weeks, followed by a 
live long production of IgG. 
 
 
In the first weeks after primary infection, an increase in viral RNA copies in the blood 
can be observed, which reaches its peak after 4-12 weeks post infection. Almost in 
parallel, the CD8+ T-cell population increases and patients show typical flu-like 
symptoms. Serum antibodies against viral proteins, mainly against p24, can be 
detected in Western blots, an observation called seroconversion, several weeks after 
virus exposure. 
Following this viral peak, a significant drop of viral load in the blood is accompanied 
by a significant decrease of CD8+ cells; the immune system seemingly controls the 
infection. After this so-called acute phase of infection, the viral load in the blood may 
reach nearly undetectable levels or remain high, the so-called viral setpoint, which 
influences subsequent disease progression (Figure 4). This latent phase of infection is 
 
Fig. 4 | Immune responses to HIV infection, 
Showing Plasma HIV levels, HIV-specific CD8+ T 
cells, and HIV-neutralizing antibodies. [1] 
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deceiving. Although no replicating virus may be detected in the blood in some 
individuals, the virus is still replicating in two important latent reservoirs [29, 30]; the 
lymph nodes and, to some extent, the brain. Of note, during this phase of infection, 
only 0.005% of the lymphocytes are actively producing virus, but 0.5% and 0.05% of 
the lymphocytes contain non-integrated and integrated provirus, respectively [31, 32]. 
Besides this fact, almost all mucosally transmitted viruses use R5 and therefore 
primarily infect memory T cells with a half life of 22 weeks only [13]. Knowing this, 
it is clear how HIV is able to escape immune responses but maintain its replication 
and overwhelm the host with time. 
During the course of infection (Figure 5), virus tropism can change as a result of 
mutations in the V3 loop of gp120 and the virus now uses also CXCR4 as a 
coreceptor to broaden its tropism to naïve T cells. This results in a sharp decline of 
CD4+ cells and renders the host susceptible to opportunistic infections and 
malignancies, leading to the acquired immunodeficiency syndrome, by definition at  




The duration of the latent phase varies among patients and allows categorizing 
patients according to their disease progression profile: rapid progressors (RP), slow 
progressors (SP) and long-term non-progressors (LTNP), with the latter living more 
 
Fig. 5 | Schematic diagram of the course of HIV-1 infection. This diagram 
illustrates the relationship between HIV-1 virus load (red line) and CD4+ T-cell 
count (blue line) over time in a typical case of untreated HIV-1 infection. DCs, 
dendritic cells. [3] 
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than 10 years after infection without progression to AIDS. There is a variety of 
factors believed to play a role in the differing duration of the latent phase: 
First, the viral load: the viral set point (see above) after acute infection predicts the 
outcome of the disease. The viral load of LTNP in the steady state is up to 20 times 
lower than those in RP [33, 34]. Second, the immune system: RPs show a lower 
diversity in the env region than quasi species of LTNPs, indicating a higher selection 
pressure by the immune system for the virus in LTNP [35, 36]. Third, the viral 
regulatory and accessory genes vpr, vpu, vif, rev, nef and tat can also play an important 
role. Their role in the replicative cycle and for the shielding against the immune 
system is explained in chapter 1.1.2.3 and 1.2.3. Fourth, chemokine receptors play a 
crucial part in determining the course of progression. Studies revealed that an 
extension in the V2 domain of gp120, responsible for the co-receptor usage, is only 
found in SP or LTNP. It is believed that this change in V2 keeps the virus from 
switching from CCR5 to CXCR4 and thereby prevents the naïve CD4+ cells to get 
infected [36-38]. Moreover it was found that in LTNP, CD8+ T cells secrete the 
natural ligands of CCR5, macrophage inflammatory protein 1α (MIP1α; CCL3), 
macrophage inflammatory protein 1β (MIP1β; CCL4) and RANTES (regulated on 
activation, normal T cell expressed and secreted; CCL5), to a higher extent. Fifth, the 
host genetic background: different HLA class I or MHCI, respectively, present 
different peptides of the virus to cytotoxic T lymphocytes and thus affect the quality 
of the immune response as some peptides are more conserved than others. HLA types 
associated with slow progression of infection are HLA-B27 and HLA-B57 [39]. Also 
homozygosity at the HLA class I loci is associated with rapid progression of infection. 
Last, a very prominent finding renders around 1% of the Caucasian population 
relatively resistant to HIV infections: the homozygous CCR5∆32bp deletion, leading 
to a non-functional receptor protein [40].  
 
1.2.2 The Immune Response to HIV 
 
The first line of defense after infection is mediated by the cellular immune response. 
Natural killer (NK) cells lyse infected cells. CD4+ cells recognize viral peptides 
presented on dendritic cells via the MHC class II molecule, whereas CD8+ T cells 
(cytotoxic T lymphocytes, CTL) get primed for viral peptides presented on MHC 
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class I molecules and also lyse infected cells. CD4+ T cells start producing and 
secreting cytokines: TH1 (T helper cells type 1) mainly produce interleukin 2 (IL-2) 
and interferon gamma (IFN-γ), thereby activating NK cells and macrophages. TH2 
cells produce IL-4, IL-5, IL-6 and IL-10, which leads to activation of the humoral 
immune response. The cellular immune response can be nicely observed in the acute 
phase of infection, where the CTL response correlates with the decrease in viral load 
and the first drop in CD4+ cell count but is not able to clear the virus because of  
reasons depicted earlier. 
 
The second line of defense is represented by the humoral immune response: TH2 cells 
produce IL-4, IL-5 and IL-6, which activates differentiation of B cells and antibody 
production in plasma cells. These antibodies are mainly directed against the viral 
envelope proteins gp120 and gp41 and the capsid protein p24, and play an important 
role in complement activation, opsonization and phagocytosis, antibody-dependent 
Fig. 6 | How antibodies combat HIV-1 a | Neutralization of free virus by antibodies, b |
complement-mediated lysis of free virus and infected cells triggered by antibodies, c | opsonization of 
virus particles by antibodies and phagocytosis of virus particles via Fc- or complement-receptors, d |
antibody-dependent cellular cytotoxicity (ADCC) against infected cells. Neutralizing antibodies 
(red), non-neutralizing (blue), Fc-receptors (violet), complement components (light-blue), 
complement-receptors (black). [2] 
 23
cellular cytotoxicity (ADCC) and neutralization (Figure 6). Their neutralizing effects 
can be shown, but viral strategies make it difficult for the host to maintain good 
neutralizing antibody titers, which will be discussed in the following two chapters. 
 
1.2.3 Immune Escape Mechanisms of HIV 
 
Why and how a virus with only a 10 kb genome is able not only to hide from the 
immune system, but also to use it for its spread and against the host is fascinating. In 
this chapter, the manifold mechanisms with which HIV is able to hide and escape the 
immune mechanisms will be introduced. 
One mechanism also used by many other viruses, the establishment of latent 
infection, is achieved by HIV through infecting resting T cells and integration of its 
proviral DNA into heterochromatin regions, which get expressed after activation of 
the cell. Additional targets that harbor latent viruses might include DCs, monocytes, 
astrocytes and seminal cells. HIV is also able to hide from immune responses by 
establishing a viral reservoir in the central nervous system, where cell-mediated 
immune response is reduced, by infecting microglia. 
Another potent mechanism of HIV to escape CD8+ T cells is the mutation of 
prominent antigenic patterns of viral proteins, resulting in escape mutants. Selection 
and fitness gain or loss of such mutants by CTLs is probably one of the main features 
of a HIV infection. These escape mutants are products of virus replication and 
mutation rates and altered antigenic patterns of viral proteins thus preventing CTL-
mediated killing of infected cells. The strong selective pressure and the resulting 
escape was shown by Koenig et al. [41], where a patient was treated with his own 
CTL clone, specific for a Nef epitope. Selection pressure and escape mutations 
resulted in the accumulation (30% of total virus) of a quasi-species that had deleted 
the presentation-relevant region in Nef. This pressure also explains the prevalence of 
humans with HLA-B27 and B57 to slow progression to AIDS (as explained in 1.2.1). 
Both select for epitopes in a well conserved and functionally important region of Gag 
p24; three distinct mutations were shown to be necessary for the virus to escape [42, 
43]. 
Many viruses that establish long-term infections, such as members of the hepatitis 
virus family, typically alter MHC class I-mediated antigen presentation. Not 
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unexpectedly, HIV is no exception, as it decreases the expression of MHC class I 
molecules on the cell surface through Nef, a product of the early viral genes. Nef 
interferes with the migration and persistence of MHC class I-antigen complexes to 
and on the cell surface of infected cells. Interestingly, Nef has no enzymatic activity 
and carries out its function by protein-protein interactions only. There are two 
pathways for Nef dependent MHC class I down regulation. In the clathrin-dependent 
pathway, Nef connects the cytoplasmic tail of MHC class I with clathrin-coated pits, 
thereby triggering endocytosis. Nef is also able to down regulate CD4 in this manner, 
to ensure that released virions are fully infectious by making sure that gp120 is free to 
bind CD4 and chemokine receptors on recipient cells. In the clathrin-independent 
pathway, Nef mediates the internalization of MHC class I molecules into ARF6-
specific early endosomal compartment [14] (Figure 7). 
To avoid the trap of being lysed by NK cells, Nef is only specific for HLA-A and 




















But not only does HIV simply hide away from the host immune response, it also 
developed a way of striking back. In vivo experiments have shown that infection of 
lymphatic tissue with HIV is accompanied by enhanced apoptosis, which mainly 
affects bystander cells [44, 45]. This is a result of Nef-mediated up regulation of FAS 
 
Figure 7 | Nef-induced downregulation of expression of MHC class I molecules and CD4.  
A | Nef accelerates the endocytosis of MHC class I molecules through the phosphofurin acidic 
cluster sorting protein 1 (PACS1)/phosphatidylinositol 3-kinase (PI3K)-dependent activation of 
ADP ribosylation factor 6 (ARF6)-mediated endocytosis (a). Nef is probably targeted first to the 
trans-Golgi network (TGN), where it acquires the ability to activate PI3K (b). The formation of 
phosphatidylinositol-3,4,5-triphosphate (PtdInsP3) ensues, which recruits the guanosine exchange 
factor ARNO to the plasma membrane, where ARF6 becomes activated (c). Together with Nef, 
the latter mediates the internalization of MHC class I molecules from the plasma membrane to an 
ARF6-specific early endosomal compartment (d). From there, MHC class I molecules are retrieved 
to the TGN, where they remain trapped (e). To explain the target specificity of this process, an 
interaction between Nef and the cytoplasmic tails of HLA-A and HLA-B is probable, although it 
remains to be shown formally. B | The two steps of Nef-induced CD4 downmodulation. At the 
plasma membrane, Nef connects the cytoplasmic tail of CD4 with clathrin-coated pits through an 
interaction with adaptor protein 2 (AP2) and the vacuolar ATPase (v-ATPase), triggering rapid 
endocytosis of the CD4 receptor (a). 
In the early endosome, Nef then interacts with the COPI coatomer (a coat structure of early 
endosomes), which targets CD4 for lysosomal degradation (b). An as-yet unidentified co-factor (X) 
potentiates the interaction between Nef and the COPI coatomer. Activation of PI3K and ARF6 is 
shown as a change in colour from light to dark.
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ligand (FASL) on the surface of infected cells. And as almost all HIV-specific T cells 
express FAS on their surface, they get killed by apoptosis before starting an efficient 
immune response. The mechanism how Nef up regulates FASL, however, is not yet 
known. 
Although HIV infections trigger bystander cell apoptosis, Nef inhibits apoptosis in 
infected cells, at least until the cell has produced its load of new virions. Taken 
together, Nef inhibits the apoptotic signaling molecules apoptosis signal-regulating 
kinase 1 (ASK1), BCL-2 antagonist of cell death (BAD) and p53. 
The last method of HIV to escape an immune system is to impair its response. CD4+ 
T cells are important for priming dendritic cells to initiate CD8+ T-cell responses, to 
maintain memory T cells and maturation of CD8+ T-cell function. All of these 
actions are impaired by the CD4+ cell specificity of HIV.  
 
1.2.4 The Neutralization and Neutralizing Antibodies 
 
Antibody (Ab)-mediated neutralization plays a key role in the fight against many 
pathogens and is defined as a measurable loss of infectivity due to direct and dose-
dependent activity of Abs. Neutralizing antibodies (nAbs) will likely be required in 
the development of a vaccine to protect against HIV-1. In fact, classical HIV/AIDS 
vaccine approaches have failed to protect or have tended to elicit rather weak nAb 
responses. However, passively administered nAbs have shown to be protective in 
animal models [46-53] and therefore, a better understanding of nAb production and 
Ab-mediated neutralization is sufficient for further success in the HIV vaccine field. 
The targets of nAbs on HIV-1 are conserved motifs presented on functional envelope 
(Env) spikes (see Chapter 1.1.2.1). Relatively conserved regions of Env have been 
identified and contain elements crucial for a variety of functions in vivo (i.e. Env 
synthesis, folding, processing, virus incorporation, stability, receptor recognition and 
fusogenicity [54]). The most crucial challenge for vaccine-elicited nAb responses is to 
be high in titer and broad in recognition of different virus isolates, so that virus escape 
cannot occur by minor mutations. 
There are some drawbacks in getting nAbs to work. Problematic issues are not only 
the fast change of the virus by mutations, the shielding of nAb epitopes by variable 
loops and glycans and the steric inhibition of Ab binding, but also the 
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Figure 8 | The trimeric Env spike of HIV-1/SIV a | Electron micrographs of SIV particles 
showing trimeric Env spikes on the surface (63). This micrograph shows trimers on the surface of 
an SIV particle expressing high levels of Env. HIV-1 Env appears to be less stable than Env of SIV, 
and there is likely heterogeneity in the number of Env spikes per virion. b | Model of the Env spike 
based on the structure of core gp120 (11, 64), with three gp120 monomers shown in gray, pale 
green, and pale blue. gp41 is shown schematically as three pink tubes. Carbohydrate chains are 
shown in yellow, and the oligomannose cluster proposed to interact with mAb 2G12 is shown in 
cyan. The approximate locations of the epitopes for broadly neutralizing mAbs are indicated. [5] 
immunodominance of non-neutralizing epitopes (formed by non-functional Env; i.e. 
mono-, dimers and gp41 stumps), which often overlap with epitopes for broadly 
nAbs. But these non-neutralizing Ab could play important roles in immunological 
pathways other than neutralization, e.g. for complement activation, opsonization, or 
most importantly, ADCC.  
As HIV-1 only needs one [55] to five [56] spikes for infection, nAb clearly need to 
reach high titers to successfully neutralize virus in vivo.  
With all these limiting factors being of concern, there are a few monoclonal Abs 
(mAbs) described to date that can potently neutralize a wide range of primary HIV-1 
isolates. Briefly, neutralizing mAbs (nmAbs) against gp120 are b12 and 2G12, whose 
epitopes overlap with the CD4 binding site and a distinct cluster of glycans on the 
outer face of gp120, respectively. Neutralizing mAbs against gp41 are 2F5 and 4E10, 
which target epitopes within the membrane-proximal external region (MPER) of 
gp41 [54] (Figure 8). A drawback for the latter two was the finding that both cross-
react with cardiolipin through a hydrophobic tip in the CD3 region and therefore are 
autoreactive [57].  
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There are many more mAbs showing weaker neutralization profiles (e.g. Z13e1, D5). 
Interested readers are referred to some reviews about neutralizing monoclonal 
antibodies in the HIV-1 vaccine field [51, 58-62]. 
All these mAbs have become vital tools not only for studying neutralization 
mechanisms, but also for characterizing Env vaccine candidates. 
Neutralizing Antibodies, monoclonal or polyclonal, will play an important role in the 
fight against HIV-1 infections and in the development of a vaccine since only nAbs 
are able to prevent a primary infection.  
 
1.3 HIV Vaccine Development 
 
The problem with the natural immune response to HIV is that it is always chasing the 
persisting, variable virus. In these circumstances, the virus will always escape. Due to 
this fact and the high mortality, a prophylactic vaccine is desperately needed [63]. 
Since 1798, classical vaccination strategies have worked for a number of infectious 
diseases, but not for HIV infections. Thus far, no one has ever cleared an HIV-1 
infection and because of the unique immunological properties of HIV-1, classical 
vaccine designs have failed. 
In today’s HIV vaccine research field, there are two main strategies: One is to 
investigate and develop vaccines inducing neutralizing antibodies, the other is to 
generate HIV-specific CD8+ T cells. 
The best vaccine-induced immune response would be the production of neutralizing 
antibodies, as; if present in high enough titers and with cross-clade neutralizing 
capacity; true sterilizing protection could be achieved. 
As the search for adequate nAbs clearly became very difficult and there still might be 
the danger of cell-to-cell transmission, a vaccine-induced cellular immune response 
becomes important too. HIV-specific CD8+ T cells could then kill infected cells 





1.3.1 Neutralizing Antibody Vaccines 
 
When HIV was first identified and sequenced, many thought it would be straight 
forward to use the viral gp120 to create a vaccine. But because of the high variability 
and the irrelevance of monomers to mediate neutralization in vivo, these first attempts 
were thwarted and more than two dozen phase I clinical trials [64] and two phase III 
efficacy trials in the United States and Thailand showed no protection against 
infection.  
The new idea then was to create live attenuated, nef-deleted viruses as vaccine 
candidates. Shortly after the initial hope that nef-deleted viruses may be used as 
vaccines, the group of Dr. Ruth Ruprecht showed that live attenuated viruses 
represent safety problems as monkeys infected with nef-deleted viruses developed 
disease [65, 66]. 
The field then concentrated on nmAb production and on screening of nmAb by 
establishing the SHIV/macaque model. Several SHIV challenge experiments also 
provided proof-of-concept that passively administered nAb can protect monkeys from 
infection [47-50, 52, 53, 67]. With this positive note and the fact that conserved 
regions do exist in the structure of HIV Env, a better understanding of the different 
forms of Env (unbound/bound and Env of early isolates vs. so-called late Env) will be 
sufficient for more successful SHIV trials and identification of more nAb or 
neutralization susceptible epitopes.  
 
1.3.2 T-Cell Stimulating Vaccines 
 
Induction of CD8+ T cells by vaccination with vectors encoding HIV genes (plasmid 
DNA, modified vaccinia virus Ankara (MVA), adenovirus carrying gag, pol, nef and 
env) might offer a chance for partial protection from HIV infection. CD8+ T cells 
cannot prevent infection of cells but they could abort an infection before it becomes 
established, or contain the virus at a significantly lower level. Encouraging data arose 
from the finding that some sex workers in Nairobi are regularly exposed but not 
infected by HIV. This resistance was found to derive from HIV-specific CD 8+ T 
cells in cervical mucosal lavage samples [68]. 
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However, latently infected cells survive cytotoxic T-lymphocyte surveillance. When 
those latently infected cells become activated, they produce virions that could infect 
new cells before the initial cells die or are cleared. Thus, cytotoxic T lymphocytes help 
control the infection but do not clear the HIV reservoirs completely [1].  
 
1.3.3 The SHIV/Macaque Model 
 
SIV does not appear to cause AIDS in their natural African hosts (SIVcpz in 
chimpanzees, SIVsm in sooty mangabeys, SIVagm in African green monkeys). Similar to 
humans, however, several species of Asian macaques develop AIDS when infected 
with a common non-pathogenic lentivirus of African sooty mangabeys (SIVsm became 
SIVmac).  
SHIV constructs encode HIV-1 env in the genome of SIVmac and rhesus macaques 
infected with such SHIVs show similar pathogenesis leading to AIDS as HIV-1-
infected humans do.   
SHIVs are unique in that they allow direct testing of HIV-1 Env-based vaccines and 
neutralizing antibodies isolated from HIV-1-infected individuals in an animal model 
and primate-tested active and passive immunization can directly enter clinical trial. 
Other important advantages are the isolation of new HIV-1 Env neutralizing 
antibodies from infected primates and the possibility of envelope evolution studies in 
the primate model [69]. 
New SHIV constructs should therefore fulfill some criteria to be biologically relevant: 
A) As >50% of all individuals with HIV/AIDS harbor HIV-1 clade C infection, 
the development of anti-clade C vaccines should be a top priority. To date, 
however, most primate challenge studies use clade B SHIV strains.  
B)  The majority of HIV-1 infections happen during sexual intercourse by 
mucosally transmissible R5 viruses. 
C) According to an intriguing study [70], recently transmitted HIV-1 clade C 
isolates surprisingly showed higher neutralization sensitivity. Compared to the 
predominant quasispecies from a donor, their sexual partner harbored more 
neutralization sensitive viruses. This finding suggests a bottleneck, which 
favors neutralization-sensitive quasispecies during or shortly after 
transmission. 
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New SHIV constructs therefore should carry HIV-1 clade C env, be mucosally 







As most SHIV constructs are clade B but >50% of all individuals harboring 
HIV/ADIS worldwide are infected with clade C, the group of Dr. Ruprecht 
developed a clade C SHIV from a biological isolate of an infected Zambian child 
[71]. This SHIV (SHIV-1157ipd3N4) was replication competent and more virulent 
because of an additional NFKB site engineered in the viral LTR. But as this virus was 
re-isolated from a monkey 141 weeks post infection, this SHIV represents a late-
stage, immune escape virus. A recent study [70] suggests that HIV clade C envelopes 
from late stage viruses show less neutralization sensitivity then do early biological 
isolates; a bottle neck during or shortly after sexual transmission seems to appear that 
favors  neutralization-sensitive quasispecies. Therefore, the use of SHIVs containing 
envelope of late isolates will not only set the bar high for neutralizing antibody studies 
in rhesus monkeys but also won’t mimic the natural course of infection due to their 
relatively neutralization resistance. 
The aim of this project was to engineer a novel SHIV construct on the basis of 
SHIV-1157ipd3N4. By exchanging the major part of its envelope region with the 
corresponding region of an earlier viral isolate, the new SHIV will fulfill all criteria of 
biological relevance: mucosal transmissibility, early clade C envelope and R5 tropism. 
These criteria ensure this new SHIV to be a useful tool for vaccine efficacy studies in 








3.1 Vectors and Viral DNA 
 
SHIV-1157ipd3N4 is a chimeric virus containing the SIVmac239 backbone with the 
HIV-1 clade C envelope of an isolate obtained from a Zambian infant (#1157i). The 
construct was serially passaged through five rhesus macaques (p) by blood transfer at 
week 2 post infection and caused disease (d) in the first monkey (RPn-8) after 137 
weeks. The viral DNA was re-isolated from RPn-8 at week 141, used for PCR and an 
additional NFKB site was introduced in the 3’ LTR of clone 3 to increase replication 
efficacy (3N4). 
The parental virus of SHIV1157ipd3N4, SHIV-1157ip, was re-isolated after passage 
to RPn-8 before disease developed and represents the early-stage form. 
 
 
Figure 9 | Genetic map of a viral genome carrying plasmid comprising vector SP73-N 
(red). Important restriction sites as well as ORF (yellow) and the region of envelope exchange 
(green) are indicated.  
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SHIV-1157ipd3N4 whole genome and 3’ half only (containing env) was provided as a 
plasmid containing an ampicillin-resistance carrying vector pSP73-N (Figure 9) by 





All bacterial work was done with Invitrogen MAX Efficiency Stbl2 Competent Cells. 
Genotype: 
F- mcrA Δ(mcrBC-hsdRMS-mrr) recA1 endA1lon gyrA96 thi supE44 relA1  - Δ(lac-
proAB)  
 
3.3 Cell Lines 
 
● 293T cells 
 
For the transfection of full-length viral DNA and production of viral particles, 
293T cells were used. These cells derive from SV40 Large T antigen carrying 
human embryonic kidney cells, which allow the replication of episomal DNA. 
 
● TZM-bl cells 
 
TZM-bl cells derive from HELA cells and express CD4, CCR5 and CXCR4 
as viral receptors. These cells were used in viral assays to quantify HIV 
infection since they carry a firefly luciferase and a beta-galactosidase gene under 
the control of the HIV promoter. Infection with HIV results in expression of 
both marker genes and can be detected by standard luciferase assays and/or 
staining of the cells. 







     1%  Enzymatic digest of casein 10 g/L 
   0.5%  Yeast extract (low sodium) 5 g/L 
   0.5%  Sodium chloride 5 g/L 
   0.2%  Inert agents (necessary for tableting process) 2 g/L 
Obtained from Sigma (LB Broth Tablets) 
 
● Carbenicillin 
Obtained from GIBCO (Carbenicillin, Disodium Salt) 
 
● LB Agar  
    1%  Tryptone (10 g/L) 
 0.5%  Yeast extract (5 g/L) 
    1%  Sodium chloride (10 g/L) 
 1.5%  Agar (15 g/L) 
Obtained from MP Biomedicals (LB-Agar) 
 
● SOC Medium 
   2%   Tryptone (20 g/L) 
0.5%   Yeast extract (5 g/L) 
10 mM  Sodium chloride 
2.5 mM  Potassium chloride 
10 mM  Magnesium chloride 
10 mM  Magnesium sulfate 
20 mM  Glucose 
Obtained from Invitrogen (S.O.C. Medium) 
 
 
● 10% FCS DMEM 
 88% DMEM 
 10% Fetal calf serum (FCS) 
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 1% Glutamine 
 1% Penicillin/Streptomycin   
 
● 20% DMEM 
 78% DMEM 
 20% FCS 
 1% Glutamine 
 1% Penicillin/Streptomycin 
● RPMI 
 78% RPMI minimal medium 
 20% FCS 
 1% Glutamine 
 1% Penicillin/Streptomycin 
 
 
● 0.25% Trypsin, EDTA 
Obtained from Invitrogen 
 
● Minimal Medium 
Obtained from Invitrogen 
  
● Freeze Medium 
  10% DMSO 
  90% FCS 
 
3.5 Chemicals, Enzymes and Kits 
 
● Restriction enzymes 
All restriction enzymes, BSA (100x) and their buffers (5x) were obtained from 





● 1% Agarose gel 




● 10x TAE 
 Obtained from commercial source 
 
● H2O 
For all experiments, ultrapure H2O (Sigma) was used. 
 
● Plasmid preperation kit 
To purify plasmids from bacterial cultures, Qiagens QIAprep Spin Miniperp 
Kit was used with spin columns for 5 ml and tip20 columns for 20 ml cultures 
 
● Gel elution kit 




ROCHE Rapid DNA Ligation Kit was used for ligations 
 
● Lipofectamine LTX Reagent 
 Obtained from Invitrogen 
 
3.6 Antibodies and Monkey Sera 
 
Serum from rhesus monkey RPn-8 was used as neutralizing antibody source for 
neutralization assays. Serum samples were collected 45, 65 and 100 weeks post 








4.1 Molecular Cloning 
 
Plasmid map analysis and strategy development (genetic maps, open reading frame 
search and restriction site analysis as well as the identification of an in-frame cloning 
strategy) was done with CLC Free Workbench 4.0 (CLC bio; www.clcbio.com). 
All restriction digests were done with enzymes and buffers from New England 
Biolabs in a heat block according to the manufacturer’s instruction. 
DNA and New England Biolabs 1 kb Marker for band size identification were run in 
general on a 1% agarose gel in 1x TAE buffer at 80-100V. Gel photos were taken 
with the Biorad Universial Hood II. Relevant bands were excised with sterile 
disposable scalpels and gel elution was done using the QIAquick Gel Extraction Kit. 
The ligation reaction was performed with the ROCHE Rapid DNA Ligation Kit for 




Transformation of the MAX Efficiency Stbl2 E. coli strain was done according to the 
Invitrogen protocol with minor changes. 
A stock of competent cells was thawed on wet ice together with empty polypropylene 
culture tubes used for subsequent steps. 
With the use of the Bunsen burner, 50 μl of the cell suspension was aliquoted into the 
culture tubes in a sterile manner. For transformation of isolated and purified plasmid, 
1 μl was used, for transformation of ligation mixes, 10 μl was used. 
After adding the DNA and gentle tapping, the transformation mix was incubated 20 
minutes on ice. 
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After a 30 seconds heat shock at 42°C in the water bath, the mixture was incubated 
for 2 minutes on ice, followed by the addition of 900 μl S.O.C. medium to each tube. 
To help the bacteria regenerate, the tubes were incubated 60-80 minutes at 30°C and 
150 rpm. 
The cultures were then plated out on LB Agar containing 50 μg/ml carbenicillin in a 
low concentration (100-110 μl of the transformation mix added to the plate) and in a 
high concentration (the left over ~900 μl of the transformation mix was centrifuged 10 
minutes at 3000 rpm, most of the supernatant was discarded, the bacterial pellet 
resuspended in the leftover and plated out).   
 
4.3 Glycerol Stocks 
 
In a 1.5 ml tube, 0.5 ml autoclaved 30% glycerol in ddH2O was added to 0.5 ml of the 
culture (in logarithmic growth phase). After gently inverting the tubes, the stocks 
were shock frozen using liquid nitrogen or dry ice/ethanol and stored at -80°C. 
 
4.4 Plasmid Isolation 
 
Plasmid isolation was done according to the Qiagen Protocol for Spin columns and 
tip-20 tubes (QIAprep Spin Miniprep/Midiprep Kit), respectively. 
 
4.5 Freezing and Thawing of Cells 
 
To freeze mammalian cells, 2x106 cells were transferred to a cryo tube with 1 ml of 
freeze medium. The cells were frozen using a Nalgene cryofreezer and stored 24 hours 
at -80°C before transfer to a liquid nitrogen freezer for long time storage. Thawing of 
frozen cells was done by taking out the tube and putting it into a 37°C water bath 
immediately. The aliquot was then transferred to a 15 ml Falcon tube with 5 ml 10% 
FCS DMEM media. To wash the cells, the tube was gently mixed and then 
centrifuged 5 minutes at 1000 rpm. 
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The supernatant was aspirated and the pellet was gently resuspended in 5 ml 10% 
FCS DMEM, followed by transfer to a T75 culture flask already containing 10 ml 
10% FCS DMEM. 
 
4.6 Preparation of Media and Maintaining of Cell 
Lines 
 
For preparation of media, the single components were warmed up in the 37oC water 
bath, mixed together into a 250 ml filter unit and sterilized through a 0.2 μm filter by 
applying vacuum. The flask was closed, labeled and stored at 4°C. 
Before splitting the cells, the media and Trypsin-EDTA bottles were pre-warmed to 
37°C in the water bath. 
The splitting of cells was performed every 3-4 days, depending on the cell density and 
the media color in the culture flask. The supernatant was aspirated, 5 ml warmed 
(37°C) Trypsin-EDTA was added (all values related to T75 culture flasks) to the flask 
and incubated approximately 3 minutes at 37°C. When the cells detached, 5 ml 
warmed 10% FCS DMEM was added to rinse the flask. The whole cell suspension 
was mixed thoroughly; 1 ml was transferred to a 15 ml Falcon tube and centrifuged 5 
min at 1000 rpm. After aspirating out the supernatant and gentle resuspending the 
pellet by tipping against the tube, 5 ml of media (10% FCS DMEM) was added. 
Further resuspending of the cells, transfer to the culture flask (already containing 10 
ml fresh media), gentle swivel, marking the date on the flask and putting back the 
flask into the incubator (37°C, 5% CO2) finished the procedure. 
 
4.7 Transfection and Production of Viral Particles 
 
Transfection of 293T cells was performed using the Lipofectamin LTX and Plus 
Reagent from Invitrogen. In a 12-well plate, 104 cells/ml were plated per well one day 
before transfection to allow the 293T cells to adhere to the bottom. 
For transfection, 200 μl minimal medium, 2 μg of DNA and 1 μl of Plus Reagent was 
added to Eppendorf tubes, mixed thoroughly and incubated 5 minutes at room 
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temperature. Five μl Lipofectamine was added to each sample, mixed thoroughly and 
incubated again 30 minutes. In the meantime, the media supernatant from the cells 
was discarded and 200 μl minimal medium was added to each well of cells and put 
back into the 37°C incubator. 
After half an hour incubation of the transfection mixture, all ~210 μl were added to 
the wells (pos. control DNA was added each time in one well as transfection control) 
and incubated again for 3-4 hours at 37°C before adding ~600 μl DMEM (20% FCS) 
to each well, making the FCS concentration roughly 10% again. The plate was put 
back to 37°C and kept there for 24 hours and then transferred to the biocontainment 
suite, as viral particles were produced by these cells. To obtain virus, the supernatant 
from the transfected 293T cells was simply harvested for each clone, filtered through a 
0.2 μm syringe filter unit and stored at -80°C. 
 
4.8 The TZM-bl Assay 
 
On day one, white 96-well luminometer-read out plates were seeded with 100 μl/well 
of TZM-bl cells at 5x104 cells/ml (diluted in 10% FCS DMEM), 9 wells in the 
bottom line were left empty for controls and the plate was incubated over night at 
37°C. 
 
On day two, viral dilutions (usually 1:5 serial dilution) were performed in a separate 
96-well plate at an end volume of 100 μl in 10% FCS DMEM per well. To increase 
infectivity later on, 10 μl of a 400 μg/ml DEAE dextran was added to each well of the 
virus dilution.  
 
After carefully removing the 100 μl medium from each well of the TZM-bl plate, 110 





Figure 10 | Pipetting scheme for the TZM-bl assay for 4 clones 
in a triplicate for each 96-well plate (red, turquoise, green, yellow) 




The plate was incubated at 37°C, 5% CO2 over night. 
 
On day three, the medium was replaced. 
On day four, 100 μl/well luciferase substrate (Bright Glo Luciferase, Promega) was 
added to each well and the plate was read in a Luminometer (PerkinElmer VICTOR 
Light 1420 Luminescence Counter). 
 
4.9 The p27 Assay 
 
Measuring the amount of SIV p27 (homologous to HIV p24) by a sandwich ELISA 
enables the quantification of the viral load in tissue culture samples. For this, 25 μl 
distribution buffer was added to each well of a micro-ELISA plate coated with anti-
p27 murine mAb. Then, 100 μl SIV p27 standard dilution, cell-free samples of virus-
infected PBMCs taken at different time points, or negative control (medium only) 
were added to the wells in triplicates. Following a 60 minute incubation time at 37°C 
and four washing steps, 100 μl of conjugate solution (peroxidase-conjugated mixture 
of monoclonal antibodies to SIV p27) was added to each well. The wells were then 
covered with a plate sealer and incubated again at 37°C for 60 minutes. After another 
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four washing steps 100 μl Peroxidase Substrate was added to each well, incubated for 
30 minutes at room temperature followed by adding 100 μl of Stop Solution. 
Absorbance at 450 nm was then measured in a micro-ELISA plate reader.  
The ELISA was done with all solutions and materials provided by Advanced 
BioScience Laboratories, Inc; SIV p27 Antigen Capture Assay.  
 
4.10 Generation of Viral Stocks in rmPBMC 
 
To grow viral stocks in PBMC derived from rhesus macaques (RM) (purified by 
Ficoll gradient centrifugation), one stock of RM PBMC was thawed, activated by IL-
2 (20 μg/ml) and transferred to a 12 well plate. 
These cells then got infected with a molecular clone (filtered supernatant of 
transfected 293T cells) and TNF-α (10ng/ml) was added for optimal virus replication. 
Every two days, supernatant was collected and filtered through a 0.2 μm syringe filter 
unit. For p27 measurement, 100 μl were transferred to another plate; the rest was 
frozen as viral stock at -80°C.  
 
4.11 The Neutralization Assay 
 
TZM-bl based neutralization assays of SHIV-1157ipd3N4 and SHIV-1157ipEL 
were performed with autologous sera from the monkey of viral origin, RPn-8. The 
protocol was the same as for the TZM-bl assay with the only change that the virus 
concentration was constant and the serum was serially diluted. 
The readout was done after addition of Luciferase substrate with the Luminometer 







Figure 11 | Schematically diagram of the cloning strategy The pSP-73N plasmid (light grey) with the 
SHIV-1157ipd3N4 backbone and its env (yellow) which gets substituted by the early SHIV-1157ip env (green) 
are shown. The indicated restriction enzymes (red) provide the two way strategy, the substitution of env and the 





5.1 Molecular Cloning of SHIV-1157ipEL 
 
To avoid problems associated with working on a big construct, in this case 13kb, and 
to get rid of multiple restriction sites, a two-way strategy was devised (Figure 11): 
Briefly, the exchange of the env gene was done as the first step in the 3’ half of the 
viral genome only. After screening for positive clones, the 3’ half carrying the new 
envelope was fused in the second step with the 5’ half of SHIV-1157ipd3N4, 
resulting in a full-length virus again (see a. and b.). 
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a. Substitution of the late envelope 
To substitute the late env of SHIV-1157ipd3N4 with the early env of SHIV-1157ip, 
we identified KpnI and BamHI as two restriction sites allowing a substitution of the 
major part of the env, spanning most of gp120 as well as the entire gp41 extracellular 
domain and the transmembrane region (Figure 11). The resulting 2.1 kb fragment, 
representing the early env of SHIV-1157ip and the 4.2 kb fragment, representing the 
vector pSP73-N plus the Δenv SHIV-1157ipd3N4 3’ were excised on an UV bench 




















Figure 12 | Gel extraction scheme Picture of the cut gel after digestion of SHIV-1157ipd3N4 and 
SHIV-1157ip with the enzymes KpnI and BamHI. Cut out bands represent the 4.3kb fragment of the 
late 3’ half backbone without the major part of env and the 2.1kb fragment of the early SHIV-1157ip 
env, respectively. 
  
The purity, size and concentration of the extracted DNA was confirmed on a gel 
(data not shown), and equal amounts of SHIV-1157ip env and Δenv SHIV-
1157ipd3N4 3’ backbone were ligated and transformed into Sbl2 cells. All bacterial 
growth was done at 30°C and 150 rpm, as suggested for cloning of retroviral 
constructs to maximize the yield of positive clones. 
Transformed cells were plated out, grown overnight and the next day, colonies were 
picked and inoculated in 5 ml LB/carbenicillin and cultured for ~16h at 30°C, 150 
rpm. 
Following the preparation of glycerol stocks of all ten clones and re-isolation of the 
plasmid DNA, a screening for positive clones was performed. 
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The identification of positive, early envelope-carrying clones was possible due to a 
unique PvuI restriction site in the sequence of the early envelope, resulting in a unique 
1.4 kb fragment after double digestion with PvuI and BglII (Figure 11 and Figure 13). 
Figure 13 shows the result of the screen after this first step. Restriction with PvuI and 
BglII leads to the desired 1.4 kb fragment for all ten clones (see arrow), thus all 
screened clones are positive and represent the early envelope of SHIV-1157ip in the 3’ 




Figure 13 | Screening and identification of positive clones Plasmid DNA of 10 clones was 
digested with BglII and PvuI, resulting in a 1.4kb fragment, unique for positive clones. 
 
 
b. Construction of full length virus containing the early envelope 
To construct a full-length virus, clone 8 was picked for further ligation with the 
SHIV-1157ipd3N4 5’ half. This was done with a 5’ half comprising the pSP73-N 
vector provided by Siddappa N. B. (Figure 14 b) “p5’”), as well as with a newly eluted 
5’ half (plus vector) of the original SHIV-1157ipd3N4 plasmid (Figure 14 b) “5’ from 
1157ipd3N4”). Clone 8 was digested with the restriction enzymes SphI and NotI, 
resulting in a 3.9 kb fragment, representing the 3’ half without the pSP73-N vector, 
and ligated with the 9kb fragment comprising the entire 5’ half of SHIV-1157ipd3N4 
and the pSP73-N vector of either p5’ or the newly excised 5’ half of the original 
SHIV-1157ipd3N4 vector (Figure 14). 
 






Figure 14 | Gel extraction and ligation scheme for full length clones Fusion of the 5’ half of 
SHIV-1157ipd3N4 with the rearranged 3’ half comprising the early env. a | Gel cut and gel 
elution control of the 3.9kb band representing the 3’ half backbone only. b | Gel cut and gel 
elution control of the 9kb 5’ half backbone plus pSP-73N vector derived from a provided plasmid 
(p5’ ) and from the original SHIV-1157ipd3N4 plasmid  
 
Stbl2 cells were transformed with the ligation mix, 12 colonies were picked from the 
plate and screened for positive clones and used for glycerol stocks and minipreps as 
previously described. 
Seven out of 12 clones showed bands of different size, which sum up to the desired 13 
kb, including the unique 1.4 kb band and thus were positive (Figure 15).  
 
Clone   1        2        3      4       5      6     7/M    8  9      10    11     12           undig. clones
1.4kb




























Scheme of the BglII + PvuI restriction strategy
Figure 15 | Full length clone screen a | Screening of positive full length clones using BglII and PvuI 
which resulted in a 1.4kb fragment, unique for positive clones (red arrow). Positive clones are indicated 
by a red plus symbol. b | Control gel – the 1.4kb band exclusively appears in the lane of the rearranged 
clones, not in the 5’ alone or the original SHIV-1157ipd3N4. Also indicated the size shift from the 
rearranged 3’ half (3’ clone 8) to the full length clones (clone 3 and clone 9) of final ~13kb. 









This virus, as it encodes an early envelope (1157ipE) in a late biological backbone (L), 
is named SHIV-1157ipEL.  
 
5.2 Testing the Functionality of Clones 
 
To identify functional, infective virus from large amounts of clones, the TZM-bl 
assay is the method of choice. TZM-bl cells are HeLa derived cells stably expressing 
CD4, CCR5 and CXCR4 as viral receptors and co-receptors, respectively. 
They are also engineered to carry a luciferase gene under control of an LTR derived 
from virus and therefore, luciferase is expressed when viral Tat is present in the cell, 












Figure 16 | Functionality of the clones in TZM-bl assay 
TZM-bl cells were infected with different dilutions of supernatant from virus 
producing 293T cells. Functional virus infects TZM-bl cells and activates LTR-
controlled luciferase. Luciferase activity is then measured with a luminometer and 
plotted against dilution. All 7 clones are positive; the variation in relative light units 
(RLU) likely is based on different viral production in 293T cells.  
 
If the clones are positive in functionality, first, the viral particles produced from the 
293T cells after transfection are infective. Second, if viral disassembly and 
transcription works, viral Tat is produced in the cells which then transactivates the 
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cellular LTR-controlled luciferase construct and luciferase activity can be measured 
after addition of luciferase substrate. 
The result of the measurement can be presented as relative luciferase units (RLU) 
blotted against the dilution of the viral clones used (Figure 16). 
In case of the seven full length clones of SHIV-1157ipEL (clone #3, #5, #7, #8, #9, 
#11, #12), we could show that all clones are positive, as luciferase was produced, 
which indicates that virus has infected TZM-bl cells and produced Tat. The range in 
RLU for the corresponding clones can result from different infectivity of the clones, 
but also, and more likely, from different concentration of virus as production of virus 
in 293T cells can vary from well to well (as the supernatant of the 293T cells is 
filtered and taken as undiluted virus sample). As all clones are positive and functional, 
we took clone #7 for further analysis and for setting up a viral stock in RM PBMC.  
 
 
Figure 17 | Replication kinetics Nine different rhesus monkey peripheral blood 
mononuclear cells (rmPBMC) were infected with viral clone 7. Every two days samples 
were taken and viral p27 concentration was measured using an ELISA kit to valuate 
replication kinetics and optimal supporting rmPBMC for growth of a viral stock.  
 
To identify optimal growth support of the virus for viral stocks, SHIV-1157ipEL 
clone #7 was grown in RM PBMC from nine different macaques and daily samples 
were taken to measure the p27 concentration, which correlates with virus 
concentration, by a special p27 ELISA kit. As presented in Figure 17, the virus did 
grow in all nine RM PBMC, but with different kinetics as of genetic diversity. The 
PBMC from monkey RFn-9, for example, does not support replication very well, 
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whereas the virus replicates to a good extend in the PBMC of monkey ROz-8, RDt-9 
and ROy-9. 
The PBMC of the latter three monkeys were pooled for the growth of the viral stock. 
 
5.3 Measuring the TCID50 
 
As for future experiments it is important to know the concentration of virus used. The 
concentration of virus can be depicted in two different ways: as multiplicity of 
infection (MOI), which gives a theoretically number of viral particles per cell or as 
tissue culture infective dose 50 (TCID50). In our case, it was important to find out 
which sample of the virus grown in the pooled RM PBMC (see chapter 5.2) is the 
most infectious. Therefore TZM-bl cells were again infected with aliquots of samples 
from the viral stock frozen on different days after infection of the pooled RM PBMC 




Figure 18 | TCID50 of viral stock Different day samples (indicated on the right) of viral 
stocks were used to infect TZM-bl cells to measure the time point of highest viral load and 
tissue culture infective dose 50 (TCID50), respectively. 
 
After another luciferase activity read out shown in Figure 18, the viral load in the 
stock clearly reaches its maximum around day 12, making the viral stock from day 12 





To answer the question if we succeeded in cloning of a more neutralization sensitive 
envelope comprising SHIV, we set up a neutralization assay on TZM-bl cells with 
sera from monkey RPn-8. As SHIV-1157ip and SHIV-1157ipd3 were re-isolated 
from this monkey, the neutralization assay with these autologous sera from different 
time points of extraction gave us a great opportunity to compare the neutralization 
susceptibility of the early virus with the additional NFKB sites to the late virus, also 





Figure 19 | TZM-bl neutralization assay with RPn8 rhesus monkey sera TZM-bl 
neutralization assay for comparison of the neutralization sensitivity of SHIV-1157ipd3N4 with 
the newly engineered virus SHIV-1157ipEL. Autologous sera from rhesus monkey RPn-8, 
extracted at different time points after infection, was added to TZM-bl cells in different 
dilutions (x-axis) before addition of virus. Percent neutralization, the reciprocal RLU, is given 
on the y-axis. 
 
In comparison to the late virus SHIV-1157ipd3N4, the new virus SHIV-1157ipEL is 
neutralization sensitive for every serum sample (early serum week 45, mid-time serum 
week 65 and late serum week 100), indicated by percent neutralization, the reciprocal 
value of RLU (Figure 19). At serum dilution 1:40, 60-20% of SHIV-1157ipd3N4 
gets neutralized with the different serum samples, respectively. For SHIV-1157ipEL, 
however, neutralization around 90% can be seen for all serum samples at the same 
concentration of 1:40. This data proves that we succeeded in our attempt to create a 







The overall goal of this thesis was to generate a R5 SHIV that encodes an early, 
neutralization sensitive HIV-1 clade C env. The group of Dr. Ruprecht recently 
published an engineered late stage clade C SHIV with an additional NFKB site in its 
LTR to render it more replication competent[71]. 
We used this SHIV construct as backbone and substituted the major part of its late 
envelope with the corresponding section of an early env. 
The newly constructed molecular clone, SHIV-1157ipEL, has a number of relevant 
characteristics: 
1) SHIV-1157ipEL encodes an HIV-1 clade C env from an early, neutralization 
sensitive isolate. According to an intriguing study, recently transmitted HIV-1 
clade C isolates were surprisingly neutralization sensitive [70]. After mucosal 
transmission during sexual intercourse, recipients harbor more neutralization-
sensitive viruses compared to the strains predominant in the donor, suggesting 
the occurrence of a bottleneck effect during or shortly after transmission. The 
use of late stage viruses in the SHIV/macaque model that have undergone 
multiple rounds of neutralizing antibody selection, followed by repeated 
escapes, therefore won’t mimic the real situation of infection during sexual 
intercourse. Such viruses would set the bar unrealistically high for nAb 
challenge studies in vivo. To mimic sexual transmission in primates, SHIV 
constructs carrying env of recently transmitted, early HIV-1 isolates will be 
preferable over SHIV strains with env genes of late-stage viruses. The 
neutralization assay data in this thesis show significant higher neutralization 
susceptibility of SHIV-1157ipEL with autologous monkey sera compared to 
the neutralization sensitivity of the late stage virus SHIV-1157ipd3N4. 
2) SHIV-1157ipEL is an R5-tropic virus (data not shown). As an R5-tropic 
virus, SHIV-1157ipEL does not induce the acute, severe pathogenicity 
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typically seen within 2 weeks after infection with other, often dual tropic 
R5/X4 SHIV constructs (e.g. SHIV89.6P), which does not reflect the biology 
of HIV-1 infection in humans, which is characterized by years of clinically 
stable, chronic infection before immune exhaustion sets in. 
3) SHIV-1157ipEL contains an additional NFKB site in its LTR. An earlier 
work of this group showed a direct relation of the number of NFkB sites with 
LTR mediated gene expression [71]. This observation was used to engineer an 
additional NFKB site into the LTR of SHIV-1157ipd3N4 with the result of 
higher replication ability. As the SHIV-1157ipd3N4 backbone was used to 
incorporate the early env, SHIV-1157ipEL also includes an additional NFKB 
site, making this virus more replication competent too. 
 
Taken together, this new SHIV construct fulfils all criteria for biological relevance: 
Clade C envelope, neutralization susceptibility, replication ability, R5 tropism and 
mucosal transmissibility. SHIV-1157ipEL may therefore represent a practical tool to 
test the efficacy of vaccine candidates targeting Env of the world's most prevalent 
clade, HIV-1 clade C, in a relevant primate model and will most closely mimic the 
sexual transmission in humans. 
Currently, four rhesus macaques are infected with this SHIV for viral adaptation to 
the rhesus monkey model, and future experiments will concern evaluating virus 
behavior in vivo and monitoring disease progression of the monkeys. Other 
experiments will include investigating envelope evolutionary patterns during 
adaptation and low-dose multiple titration to identify the exact dose required for 
systemic infection. If the virus successfully replicates in these monkeys and causes 
AIDS, this SHIV construct represents a good tool for vaccine efficacy studies 
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